More and more I’m seeing a connection between the mTor pathway and metastatic prostate cancer. I just got my advanced genetic testing results back and was told…”you guessed it,” an mTor mutation. My purpose of this post is two fold:
1) To share my list of supplements for those looking for a jumping off point for what I find to be the most promising.
2) To start a discussion on mTor inhibitors and evaluate real world success or failure rates.
Written by
No_stone_unturned
To view profiles and participate in discussions please or .
AbstractDeregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.